Minxiong Hu

Minxiong Hu

Auto-generated profile, based on publicly available information

Minxiong Hu

Shengli Clinical College of Fujian Medical University, Fuzhou, 350001, China; Department of Urology, Fujian Provincial Hospital, Fuzhou, 350001, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
MHMinxiong Hu
Minxiong Hu
JLJiaxuan Liao
Jiaxuan Liao
WCWenchao Cai
Wenchao Cai
HLHang Ling
Hang Ling
DWDaoming Wu
Daoming Wu
LYLiefu Ye
Liefu Ye
Limited data from China, aim to investigate the incidence and the risk fctors of lymph node metastases in the prostatic anterior fat pad (PAFP). Patients underwent radical prostatectomy (RP) were enrolled between March 2020 to December 2022 at a single institution. Separate pathological analysis of PAFP was performed within this area. Univariate analysis and Multivariate analysis were performed to determine the risk factor of PAFP metastasis. A total of 255 patients were included. The study revealed an average age of 67.72 ± 7.07 years, with a mean total tumor volume of 41.54 ± 23.79 mL, and an average Pre-op PSA of 16.85 ng/mL. Clinical T stage was divided into T2, T3, and T4 (226, 25, 4 cases, respectively), while the Clinical M stage was categorized as M0 and M1 (248 and 7 cases, respectively). Out of the patients with PAFP, 19 (7.45 %) had lymph node in PAFP, and 3 (1.18 %) patients had metastases. In the univariate and multivariate analysis, Clinical M stage and anterior primary tumor were found to be a significant high-risk factor. Among the other 15 studies, six examined the risk factors associated with it, including anterior tumors, higher tumour volume, intermediate or high risk prostate cancer. Due to the low proportion of lymph node involvement (7.45 %) and rare tumor metastasis (1.18 %), routine separate pathological analysis of PAFP is not recommended in all RP patients unless there are anterior tumors, higher tumor volume, or intermediate/high risk prostate cancer.

1 January 2023 in Archivos Espanoles de Urologia
Verified
Journal Article
Open access
MHMinxiong Hu
Minxiong Hu
DPDanling Pan
Danling Pan
YWYongbao Wei
Yongbao Wei
LYLiefu Ye
Liefu Ye
Background: Ureteral metastasis is a rare phenomenon. Synchronous recu...